Aranscia, a global provider of clinical workflow and diagnostic technology solutions, announced today the acquisition of Spesana, a healthcare platform specializing in patient navigation, clinical collaboration, and oncology clinical decision support. The strategic move brings Spesana's founder and CEO, Carla Balch, a recognized pioneer in healthcare and oncology information systems, into Aranscia's executive leadership team as Executive Director across all software solutions.
Founded in 2019, Spesana has developed technology that accelerates the implementation and efficiency of precision medicine programs across healthcare settings. The platform's solutions for patient navigation, prior authorization, clinical trial collaboration, and diagnostic workflows are currently deployed at more than 140 clinical sites, serving major payers, provider organizations, oncology groups, and diagnostic laboratories.
Strategic Alignment in Precision Medicine
The acquisition aligns with Aranscia's mission to address tactical gaps in clinical workflows and democratize access to precision care. Spesana will join Aranscia's existing portfolio of companies that includes 2bPrecise, YouScript, and AccessDx Laboratory.
"Spesana and Aranscia have a clear and shared mission of developing and implementing best-in-class utilities that improve clinical, financial, and operational workflows for providers and the patients they serve," said Joe Spinelli, Chief Strategy Officer at Aranscia. "Carla's experience as a proven operator, builder, and ally to clinical partners makes her a perfect fit to lead Aranscia's software efforts."
One of the most significant impacts reported by Spesana clients is a 60% improvement in the appropriate use of precision medicine diagnostics. This improvement stems from the platform's ability to eliminate clinical overhead and process ambiguity through its intelligent utilities.
Leadership with Proven Industry Experience
Carla Balch brings substantial industry experience to her new role at Aranscia. Her previous positions include serving as President and CEO of Altos Solutions, which developed OncoEMR, the first web-based oncology medical records system later acquired by Flatiron Health (now part of Roche). She also served as President of Nantcare and CEO of Inteliquet, which was acquired by IQVIA. Additionally, Balch serves on the Healthcare Counsel of the Federal Reserve Bank of St. Louis.
"We built Spesana to unify fragmented healthcare workflows, and joining Aranscia allows us to realize that mission at scale," said Balch. "Our teams share a commitment to modernizing the clinician experience by eliminating technology silos and delivering a seamless, integrated, HIPAA-compliant platform across all specialties and sites of care."
Creating a Comprehensive Precision Medicine Ecosystem
The combined entity aims to deliver a more integrated approach to precision medicine implementation. Aranscia's portfolio now encompasses:
- 2bPrecise: An award-winning platform providing lab-agnostic, EMR-integrated solutions for precision care
- YouScript: A leader in personalized medication risk management and pharmacogenomics insights
- AccessDx Laboratory: A CLIA-certified, CAP-accredited molecular diagnostic laboratory specializing in pharmacogenomics and personalized diagnostics
- Spesana: A platform for patient navigation, clinical collaboration, and oncology decision support
This comprehensive ecosystem positions Aranscia to address multiple aspects of the precision medicine workflow, from diagnostic testing to clinical decision support and patient management.
Industry Impact and Future Direction
The acquisition represents a significant development in the precision medicine technology landscape, where fragmentation has been a persistent challenge. By integrating complementary technologies under one umbrella, Aranscia aims to create more seamless experiences for healthcare providers and improve patient access to appropriate precision medicine approaches.
The combined technologies particularly target improvements in pharmacogenomics implementation, infectious disease management, precision oncology, and genetic screening programs. With Spesana's reported 60% improvement in appropriate diagnostic utilization, the acquisition promises to accelerate the adoption of precision medicine approaches across healthcare settings.
Balch emphasized that the collaboration will "continue to deliver solutions that improve both patient outcomes and provider experiences and help to enable more connected, efficient, and intelligent healthcare."
